LEADER 04253nam 22005175 450 001 9910349449203321 005 20200705115346.0 010 $a3-030-17355-0 024 7 $a10.1007/978-3-030-17355-5 035 $a(CKB)4100000008959150 035 $a(MiAaPQ)EBC5848644 035 $a(DE-He213)978-3-030-17355-5 035 $a(PPN)260305359 035 $a(EXLCZ)994100000008959150 100 $a20190807d2019 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe Role of Microstructure in Topical Drug Product Development /$fedited by Nigel Langley, Bozena Michniak-Kohn, David W. Osborne 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (207 pages) 225 1 $aAAPS Advances in the Pharmaceutical Sciences Series,$x2210-7371 ;$v36 311 $a3-030-17354-2 327 $aPart I - Critical Quality Attributes: 1. Rheological Characterization in the Development of Topical Drug Products -- 2. In Vitro Release & Permeation Tests as Critical Quality Attributes in Topical Product Development -- 3. Determination of Particle Size and Microstructure in Topical Pharmaceuticals -- Part II - Role of API and Excipients: 4. Quality Assessment of API in Semisolid Topical Drug Products -- 5. The Role of Excipients in the Microstructure of Topical Semi-solid Drug Products. 330 $aFollowing the Semi-solid Microstructure Workshop sponsored by BASF and hosted by the Rutgers Center for Dermal Research, a pharmaceutical product development working group was formed. The group, known as the Q3 Working Group, selected the following five areas of focus: Particle/Globule Size and Distribution, Viscosity/Rheology/Spreadability, In Vitro Testing, State of API, State of Excipients. A committee was appointed for each of these five areas. The committees were tasked to review the literature, identify best practices, list experimental details required for an independent lab to duplicate the test, and propose scientific studies that may meaningfully advance this specific area of focus. Each committee has a chair (or co-chairs) that are the lead author(s) of the chapter. The Q3 Working Group members serve as the critical reviewers of each chapter, making suggestions that improve the quality of the document and that make each of the five chapters uniform in scope and content. Pharmaceutical development scientists that formulate topical products (creams, lotions, gels suspensions, foams, etc) and all the allied raw material suppliers, packaging suppliers, contract laboratories including CROs, CMOs and regulators need access to this book. Overall, the topic of semisolid microstructure is of equal importance to the generic pharmaceutical companies (filing Abbreviated New Drug Applications or ANDAs) and pharmaceutical companies filing New Drug Applications (NDAs). In addition to products applied to the skin, hair, and nails, The Role of Microstructure in Topical Drug Product Development crosses over and is essential reading to developers of oral suspensions, ophthalmic ointments and gels, otic suspension, vaginal semisolids and retention enemas. . 410 0$aAAPS Advances in the Pharmaceutical Sciences Series,$x2210-7371 ;$v36 606 $aPharmaceutical technology 606 $aPharmacy 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aPharmacy$3https://scigraph.springernature.com/ontologies/product-market-codes/F00008 615 0$aPharmaceutical technology. 615 0$aPharmacy. 615 14$aPharmaceutical Sciences/Technology. 615 24$aPharmacy. 676 $a615.19 676 $a615.19 702 $aLangley$b Nigel$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aMichniak-Kohn$b Bozena$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aOsborne$b David W$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910349449203321 996 $aThe Role of Microstructure in Topical Drug Product Development$92140587 997 $aUNINA